Status:
TERMINATED
Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses ofAZD2551
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Eligibility:
MALE
18-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine how well tolerated and safe AZD2551 is at different dose levels in healthy, non-smoking males. It will also investigate how quickly AZD2551 is absorbed into a...
Eligibility Criteria
Inclusion
- Provision of signed, written and dated informed consent prior to any study specific procedures
- Be willing to use barrier methods of contraception unless their partners are post-menopausal, surgically sterile or using accepted contraceptive methods
- Have a body mass index between 18 and 30 kg/m2 inclusive and weight at least 50kg and no more than 100kg
Exclusion
- Use of any prescribed or non-prescribed medication during the two weeks prior to the administration of study drug
- History or presence of conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs
- Any impairment of kidney function or laboratory results for markers of kidney function that are outside the reference range and considered clinically significant
- Underlying musculoskeletal symptoms of unknown origin, subjects with shoulder girdle musculoskeletal symptoms or Dupuytrens syndrome
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2009
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00860353
Start Date
February 1 2009
End Date
May 1 2009
Last Update
December 3 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Nottingham, United Kingdom